Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma

Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma The following diagnostic criteria are proposed to classify four clinical subtypes of HTLV‐1 associated adult T‐cell leukaemia‐lymphoma (ATL): (1) Smouldering type, 5% or more abnormal lymphocytes of T‐cell nature in PB, normal lymphocyte level (< 4 × 109/1), no hypercalcaemia (corrected calcium level < 2·74 mmol/1), lactate dehydrogenase (LDH) value of up to 1·5 × the normal upper limit, no lymphadenopathy, no involvement of liver, spleen, central nervous system (CNS), bone and gastrointestinal tract, and neither ascites nor pleural effusion. Skin and pulmonary lesion(s) may be present. In case of less than 5% abnormal T‐lymphocytes in PB, at least one of histologically‐proven skin and pulmonary lesions should be present. (2) Chronic type, absolute lymphocytosis (4 × 109/1 or more) with T‐lymphocytosis more than 3·5 × 109/1. LDH value up to twice the normal upper limit, no hypercalcaemia, no involvement of CNS, bone and gastrointestinal tract, and neither ascites nor pleural effusion. Lymphadenopathy and involvement of liver, spleen, skin, and lung may be present, and 5% or more abnormal T‐lymphocytes are seen in PB in most cases. (3) Lymphoma type, no lymphocytosis, 1% or less abnormal T‐lymphocytes, and histologically‐proven lymphadenopathy with or without extranodal lesions. (4) Acute type, remaining ATL patients who have usually leukaemic manifestation and tumour lesions, but are not classified as any of the three other types. A total of 818 ATL patients with a mean age of 57 years, newly diagnosed from 1983 to 1987, were analysed by this criteria. There were 448 males and 370 females, and 253 were still alive with a median follow‐up time of 13·3 months from diagnosis, while 565 were dead with a median survival time (MST) of 5·4 months. MST was 6·2 months for acute type, 10·2 months for lymphoma type, 24·3 months for chronic type, and not yet reached for smouldering type. Projected 2‐ and 4‐year survival rates were 16·7% and 5·0% for acute type, 21·3% and 5·7% for lymphoma type, 52·4% and 26 × 9% for chronic type, 77·7% and 62·8% for smouldering type, respectively. Distinct clinical features and laboratory findings of each clinical subtype are described. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Haematology Wiley

Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma

British Journal of Haematology , Volume 79 (3) – Jan 1, 1991

Loading next page...
 
/lp/wiley/diagnostic-criteria-and-classification-of-clinical-subtypes-of-adult-t-141yx3iuWt

References (31)

Publisher
Wiley
Copyright
Copyright © 1991 Wiley Subscription Services
ISSN
0007-1048
eISSN
1365-2141
DOI
10.1111/j.1365-2141.1991.tb08051.x
Publisher site
See Article on Publisher Site

Abstract

The following diagnostic criteria are proposed to classify four clinical subtypes of HTLV‐1 associated adult T‐cell leukaemia‐lymphoma (ATL): (1) Smouldering type, 5% or more abnormal lymphocytes of T‐cell nature in PB, normal lymphocyte level (< 4 × 109/1), no hypercalcaemia (corrected calcium level < 2·74 mmol/1), lactate dehydrogenase (LDH) value of up to 1·5 × the normal upper limit, no lymphadenopathy, no involvement of liver, spleen, central nervous system (CNS), bone and gastrointestinal tract, and neither ascites nor pleural effusion. Skin and pulmonary lesion(s) may be present. In case of less than 5% abnormal T‐lymphocytes in PB, at least one of histologically‐proven skin and pulmonary lesions should be present. (2) Chronic type, absolute lymphocytosis (4 × 109/1 or more) with T‐lymphocytosis more than 3·5 × 109/1. LDH value up to twice the normal upper limit, no hypercalcaemia, no involvement of CNS, bone and gastrointestinal tract, and neither ascites nor pleural effusion. Lymphadenopathy and involvement of liver, spleen, skin, and lung may be present, and 5% or more abnormal T‐lymphocytes are seen in PB in most cases. (3) Lymphoma type, no lymphocytosis, 1% or less abnormal T‐lymphocytes, and histologically‐proven lymphadenopathy with or without extranodal lesions. (4) Acute type, remaining ATL patients who have usually leukaemic manifestation and tumour lesions, but are not classified as any of the three other types. A total of 818 ATL patients with a mean age of 57 years, newly diagnosed from 1983 to 1987, were analysed by this criteria. There were 448 males and 370 females, and 253 were still alive with a median follow‐up time of 13·3 months from diagnosis, while 565 were dead with a median survival time (MST) of 5·4 months. MST was 6·2 months for acute type, 10·2 months for lymphoma type, 24·3 months for chronic type, and not yet reached for smouldering type. Projected 2‐ and 4‐year survival rates were 16·7% and 5·0% for acute type, 21·3% and 5·7% for lymphoma type, 52·4% and 26 × 9% for chronic type, 77·7% and 62·8% for smouldering type, respectively. Distinct clinical features and laboratory findings of each clinical subtype are described.

Journal

British Journal of HaematologyWiley

Published: Jan 1, 1991

There are no references for this article.